Ayala Pharmaceuticals Inc (ADXS)

[terry hallinan]

"I consider the info in today's PR irrelevant."

Approval of and projected commercialization of one of ADXS' vaccines by a partner this fall is "irrelevant?"

Stunning.

From the subject PR:

Nicola Mason, Ph.D., BVetMed, Assistant Professor of Medicine at the University of Pennsylvania, presented “Immune Therapy with ADXS31-164 Prevents Metastatic Disease and Prolongs Overall Survival in Spontaneous Canine Osteosarcoma.” In her presentation, Dr. Mason reviewed her experiences with ADXS31-164 in dogs with spontaneous osteosarcoma. In two separate studies, repeat administrations of up to 3.3 x 109 CFUs were well tolerated with transient low-grade side effects. Immune responses to HER2/neu were detected within 6 months in 15 of 18 dogs with minimal residual disease. In these dogs, metastatic disease was delayed or prevented. Radiographic progression of primary osteosarcoma lesions was prevented in a subset of dogs who were treated after palliative radiotherapy. Treated animals had tumor-specific T-cell responses in the tumor site and reduced numbers of Tregs and MDSCs in the tumor microenvironment.

It's just dogs but even in that case preparation for human clinical trials in juvenile osteosarcoma with much the same vaccine is proceeding.

Best, Terry